SINOTAUPHARMA-B (09941.HK): HK$34.9 Billion Margin, 782x Covered
NewTimeSpace News: On 18 November 2026, market margin financing data showed that, as at 15:56 that day, the 10 brokers tracked by the platform had extended a combined HK$34.901 billion of margin loans for SINOTAUPHARMA-B (09941.HK), equivalent to about 782 times the HK$44.61 million the company seeks to raise in its Hong Kong public offering; the offer closes on 19 November.
According to the offering documents, the company is offering 6.561 million H shares, comprising 656,100 shares (10%) under the Hong Kong public offering and 5,904,900 shares (90%) under the international placing, plus an over-allotment option of 984,200 shares. The offer price ranges from HK$52.00 to HK$68.00 per share, with a board lot of 50 shares and an entry fee of HK$3,434.29, raising HK$341 million to HK$446 million. Allotment results are expected on 23 November and listing on the Main Board is scheduled for 24 November, with GF Securities, CITIC Securities and CICC as joint sponsors.
The company is a radiopharmaceutical developer listing under Chapter 18A of the Listing Rules, with a pipeline of 13 assets; according to China Insights Consultancy, it is the first company in China to obtain marketing approval for an innovative radiopharmaceutical. Its core product XTR008, a lutetium-177 labelled SSTR-targeting radioligand for neuroendocrine tumours, is at the registration stage and is the first same-target therapeutic radioligand in China filed as a Class 3 chemical drug, while XTR004, a fluorine-18 labelled PET myocardial perfusion imaging ligand, is in Phase III. Net proceeds of about HK$329 million will be used, with 88% earmarked for R&D and registration of core products.
- LVGEM CHINA (00095.HK): Public Float Restored to 28.15%
- AKESO (09926.HK): Trustee Buys 200,000 Shares for HK$ 12 Million
- CC NEW LIFE (09983.HK): Debt Restructuring; 20% Debt Swap, 33% Option
- 3D MEDICINES (01244.HK): Envafolimab Moves to Regular Approval
- FS.COM (03355.HK): Trustee Buys 108,600 H Shares at HK$ 29.51